Real-world data show first-line chemo-immunotherapy improves survival and response rates over chemo alone in extensive-stage SCLC, supporting its broader use.
The post Combined Immunotherapy & Chemotherapy Improves Survival in Extensive-Stage SCLC first appeared on Physician’s Weekly.
